Mid-filled cell product PLX treatment COVID-19: Phase II clinical is about to be carried out
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Regenerative medicine company Pluristems Therapeutics recently announced that the FDA has approved the company's research new drug application (IND) for a phase II clinical study of PLX cell therapy for severe COVID-19 concurrent acute respiratory distress syndrome (ARDS)PLX cells are homogenous intersomes with immunomodulating properties that induce the immune system's naturally regulated T-cells and M2 macrophages, thus preventing or reversing overactivation of the immune systemPluristem believes that its PLX cells will provide a key advantage in solving the COVID-19 global pandemicThis multicenter, randomized, double-blind, placebo-controlled Phase II study will assess the effectiveness and safety of muscle-injection PLX cell therapy for COVID-19, with a primary endpoint of 28 days without a ventilatorPluristem has used PLX cells in the United States and Israel to treat serious complications caused by COVID-19 through the Compassion Use ProgramIsrael reported preliminary data on the "Sympathetic Use Plan" on 7 April 2020
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
